Anti-tumor efficacy was significantly enhanced when used in combination with other immunotherapies, including the recovery of immune responses in models with incomplete responses to anti-PD-L1 or anti-CTLA-4 monotherapy [148]. The gene discussed is CTLA4; the disease is neoplasm.